RLAY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

13.040

Open

10.500

VWAP

12.02

Vol

8.89M

Mkt Cap

2.24B

Low

10.480

Amount

106.88M

EV/EBITDA(TTM)

--

Total Shares

178.73M

EV

1.37B

EV/OCF(TTM)

--

P/S(TTM)

120.34

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Show More

Events Timeline

(ET)

2026-03-16

07:20:00

Relay Therapeutics Releases Zovegalisib Trial Data

2026-02-26 (ET)

2026-02-26

16:50:00

Relay Therapeutics Q4 Revenue $7M, Exceeds Expectations

2026-02-03 (ET)

2026-02-03

07:10:00

Relay Therapeutics Receives FDA Breakthrough Therapy Designation for Zovegalisib

2026-01-16 (ET)

2026-01-16

12:10:00

SpaceX Interviews Banks for IPO, Skild AI Raises Nearly $1.4B

2025-12-12 (ET)

2025-12-12

07:10:00

Relay Therapeutics Announces Subset Analysis of Zovegalisib Clinical Data

News

Fool

Nextech Invest Increases Stake in Relay Therapeutics

NASDAQ.COM

03-19NASDAQ.COM

Nextech Invest Increases Stake in Relay Therapeutics

Newsfilter

03-02Newsfilter

Analysis of Growth Drivers in the Biliary Tract Cancer Market

Fool

Casdin Capital Increases Stake in Relay Therapeutics

NASDAQ.COM

02-27NASDAQ.COM

Relay Therapeutics Reports 2025 Financial Results and 2026 Milestones

Newsfilter

02-19Newsfilter

Relay Therapeutics to Report Q4 and Full Year 2025 Financial Results on February 26

6 Analyst Rating

Wall Street analysts forecast RLAY stock price to rise

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

13.00

Averages

14.75

High

17.00

Current: 0.000

Low

13.00

Averages

14.75

High

17.00

H.C. Wainwright

H.C. Wainwright

Buy

maintain

$14 -> $19

AI Analysis

2026-03-23

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$14 -> $19

AI Analysis

2026-03-23

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Relay Therapeutics to $19 from $14 and keeps a Buy rating on the shares. The firm updated the company's model post the Q4 report to to reflect lower long-term operating expenses.

Citizens

Outperform

maintain

$15 -> $17

2026-03-17

Reason

Citizens

Price Target

$15 -> $17

2026-03-17

maintain

Outperform

Reason

Citizens raised the firm's price target on Relay Therapeutics to $17 from $15 and keeps an Outperform rating on the shares. Relay Therapeutics reported updated 2L+ aBC data at the 400 mg BID fed RP3D showing reproducible efficacy, best-in-class mPFS across kinase and non-kinase patients, and numerical improvement versus prior results, while doubling the Phase 2 dataset to 109 patients, reinforcing confidence in the ongoing Phase 3 trial, the analyst tells investors in a research note. The 400 mg fed regimen appears comparable to the 600 mg fasted dose without the fasting burden, and safety remained consistent with prior data, with manageable low-grade diarrhea and dysgeusia, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RLAY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Relay Therapeutics Inc (RLAY.O) is 0.00, compared to its 5-year average forward P/E of -5.74. For a more detailed relative valuation and DCF analysis to assess Relay Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.74

Current PE

0.00

Overvalued PE

-1.44

Undervalued PE

-10.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.27

Current EV/EBITDA

-10.01

Overvalued EV/EBITDA

0.22

Undervalued EV/EBITDA

-6.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

911.25

Current PS

92.86

Overvalued PS

2186.30

Undervalued PS

-363.81

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best day trade stock

Intellectia · 9 candidates

Price: $5.00 - $100.00Volume: >= 3,000,000Price Change Pct: >= $3.00Relative Vol: >= 2Beta: HighRisk

Ticker

Name

Market Cap$

Eastman Kodak Co

1.10B

Oric Pharmaceuticals Inc

995.75M

Intuitive Machines Inc

5.20B

Relay Therapeutics Inc

2.24B

Globalstar Inc

10.00B

Aehr Test Systems

1.36B

todays top stocks

Intellectia · 47 candidates

Market Cap: >= 500.00MPrice: $2.00 - $500.00Volume: >= 300,000Price Change Pct: >= $7.00Relative Vol: >= 1.50

Ticker

Name

Market Cap$

Sigma Lithium Corp

1.32B

Applied Optoelectronics Inc

6.71B

Eastman Kodak Co

911.63M

SBA Communications Corp

18.28B

Oric Pharmaceuticals Inc

1.42B

York Space Systems Inc

3.01B

predict most bullish ticker today

Intellectia · 43 candidates

Region: USPrice Change Pct: >= $5.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Option Sentiments: Bullish

Ticker

Name

Market Cap$

Eastman Kodak Co

911.63M

Satellogic Inc

816.86M

Bioceres Crop Solutions Corp

30.31M

Relay Therapeutics Inc

1.92B

Viasat Inc

6.14B

Iridium Communications Inc

2.99B

what is the best stock to day trade today

Intellectia · 101 candidates

Price: $5.00 - $50.00Price Change Pct: >= $4.00Relative Vol: >= 2Gap Pattern: GapUpMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Franklin Covey Co

186.57M

Eastman Kodak Co

911.63M

Sigma Lithium Corp

1.32B

Intuitive Machines Inc

4.39B

Satellogic Inc

816.86M

Spire Global Inc

468.45M

todays top stocks to gain?

Intellectia · 57 candidates

Market Cap: >= 300.00MRegion: USPrice: $3.00 - $500.00Volume: >= 1,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Applied Optoelectronics Inc

6.33B

Arlo Technologies Inc

1.68B

PRA Group Inc

605.63M

Figs Inc

2.57B

Dell Technologies Inc

98.13B

DENTSPLY SIRONA Inc

2.93B

what are some good swing trades under $10

Intellectia · 69 candidates

Price: $1.00 - $10.00Rsi Category: moderateMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $40.00One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Granite Ridge Resources Inc

662.82M

Patterson-UTI Energy Inc

3.07B

VivoPower International PLC

40.97M

Gaxos.ai Inc.

12.27M

Ampco-Pittsburgh Corp

158.34M

Borealis Foods Inc

34.77M

biggest earners today

Intellectia · 14 candidates

Market Cap: >= 500.00MPrice: >= $3.00Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Richtech Robotics Inc

835.65M

Redwire Corp

1.79B

HUYA Inc

846.71M

Satellogic Inc

592.67M

Corning Inc

81.28B

Cloudflare Inc

66.96B

Whales Holding RLAY

Commodore Capital LP

TCG Crossover Management, LLC

Kynam Capital Management, LP

Bellevue Asset Management AG

SB Investment Advisers (UK) Limited

ICONIQ Capital, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Relay Therapeutics Inc (RLAY) stock price today?

The current price of RLAY is 12.54 USD — it has increased 16.43

What is Relay Therapeutics Inc (RLAY)'s business?

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

What is the price predicton of RLAY Stock?

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is14.75 USD with a low forecast of 13.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Relay Therapeutics Inc (RLAY)'s revenue for the last quarter?

Relay Therapeutics Inc revenue for the last quarter amounts to 7.00M USD, decreased

What is Relay Therapeutics Inc (RLAY)'s earnings per share (EPS) for the last quarter?

Relay Therapeutics Inc. EPS for the last quarter amounts to -0.32 USD, decreased -28.89

How many employees does Relay Therapeutics Inc (RLAY). have?

Relay Therapeutics Inc (RLAY) has 192 emplpoyees as of April 03 2026.

What is Relay Therapeutics Inc (RLAY) market cap?

Today RLAY has the market capitalization of 2.24B USD.